1 easured by thermodilution) after exposure to methacholine chloride.

2 ncremental brachial artery administration of methacholine chloride (0.3 to 10 microg/min) during eugl

3 ncremental brachial artery administration of methacholine chloride (0.3 to 10 microg/min) during eugl

4                                              Methacholine chloride (0.3 to 10 microg/min) was adminis

5  before and after bronchial provocation with methacholine chloride and after reversal of provocation

6     The forearm blood flow responses to both methacholine chloride and nitroprusside were significant

7 assessed through brachial artery infusion of methacholine chloride both before and during 6 hours of

8 ons of the endothelium-dependent vasodilator methacholine chloride (Mch) and the endothelium-independ

9 ons of the endothelium-dependent vasodilator methacholine chloride (MCh) and to euglycemic hyperinsul

10 s to graded intrafemoral artery infusions of methacholine chloride (MCh) or sodium nitroprusside (SNP

11 ons of the endothelium-dependent vasodilator methacholine chloride (MCh) or the endothelium-independe

12 ons of the endothelium-dependent vasodilator methacholine chloride (Mch) or the endothelium-independe

13 superimposed intrafemoral artery infusion of methacholine chloride (Mch), an endothelium-dependent va

14 ned efficacy, safety and pharmacokinetics of Methacholine Chloride (name of study drug: SK-1211) in o

15                                   In abroad, Methacholine Chloride (Provocholine(R)) is used to meet